Phaseline

Targets › MELK

MELK (Maternal embryonic leucine zipper kinase): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Sep 2027.

Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis and splicing regulation. Has a broad substrate specificity; phosphorylates BCL2L14, CDC25B, MAP3K5/ASK1 and ZNF622. (UniProt, Q14680)

Open in Phaseline: the race on MELK, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Delcath SystemsMelphalan/HDS
High-dose melphalan delivered directly to the liver via hepatic artery infusion
MELKPhase 2Metastatic Breast Cancer in the LiverMay 2029
OncoTherapy ScienceOTS167PO
MELK kinase inhibitor
MELKPhase 1Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast CancerSep 2027

Conditions

Metastatic Breast Cancer in the Liver (1) Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer (1)

Modalities

small molecule (1)

Companies

Delcath Systems (1) OncoTherapy Science (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.